TORONTO, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Emblem
Corp. (TSXV: EMC, OTCQX: EMMBF) (âEmblemâ or the
âCompanyâ) through its wholly-owned subsidiary Emblem Cannabis
Corporation, today announced that Emblem-branded cannabis oils are
now available online through Shoppers Drug Mart to patients with a
valid medical authorization.
âAs a patient-first provider, Emblem is committed to helping provide patients access to our products through distribution channels that provide both care and convenience like Shoppers Drug Mart,â said Nick Dean, CEO, Emblem Corp. âAccessing a variety of distribution channels also continues to be a critical factor in our business strategy as we remain focused on being a leader in the medical cannabis space.â
About Emblem
Emblem is a fully integrated cannabis company focused on driving
shareholder value through product innovation, brand relevance, and
access to patient and consumer channels. Through its wholly-owned
subsidiary Emblem Cannabis Corporation, Emblem is licensed to
cultivate, process, and sell cannabis and cannabis derivatives in
Canada under the Cannabis Act. Emblemâs
state-of-the-art indoor cannabis cultivation facility and Product
Innovation Centre is located in Paris, Ontario. Emblem is also the
parent company of GrowWise Health Limited, one of Canadaâs leading
cannabis education services. Emblem trades under the ticker symbol
EMC on the TSX Venture Exchange.
For more information, please visit www.emblemcorp.com.
For media inquiries, please contact:
Deborah Rowe
H+K Strategies
416.413.4780
[email protected]
For investor inquiries, please contact:
Ethan Karayannopoulos
Investor Relations
Emblem Corp.
647.748.9696
[email protected]
Alex Stojanovic
Chief Financial Officer
Emblem Corp.
416.923.1331
[email protected]
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
INFORMATION
This news release contains certain forward-looking statements and
forward-looking information (collectively referred to herein as
âforward-looking statementsâ) within the meaning of applicable
Canadian securities laws. All statements other than statements of
present or historical fact are forward-looking statements.
Forward-looking statements are often, but not always, identified by
the use of words such as âanticipateâ, âachieveâ, âcouldâ,
âbelieveâ, âplanâ, âintendâ, âobjectiveâ, âcontinuousâ, âongoingâ,
âestimateâ, âoutlookâ, âexpectâ, âmayâ, âwillâ, âprojectâ, âshouldâ
or similar words, including negatives thereof, suggesting future
outcomes. Management of the Company believes the expectations
reflected in such forward-looking statements are reasonable as of
the date hereof but no assurance can be given that these
expectations will prove to be correct and such forward-looking
statements should not be unduly relied upon. Various material
factors and assumptions are typically applied in drawing
conclusions or making the forecasts or projections set out in
forward-looking statements. Those material factors and assumptions
are based on information currently available to the Company,
including data from publicly available governmental sources as well
as from market research and industry analysis and on assumptions
based on data and knowledge of this industry which Emblem believes
to be reasonable. However, although generally indicative of
relative market positions, market shares and performance
characteristics, such data is inherently imprecise. While Emblem is
not aware of any misstatement regarding any industry or government
data presented herein, the medical marijuana industry involves
risks and uncertainties and is subject to change based on various
factors.
Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Companyâs actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Companyâs December 31, 2017 Managementâs Discussion and Analysis, which has been filed with the Canadian Securities Administrators and available on www.sedar.com. Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.